Trevi Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Trevi Therapeutics, Inc. (TRVI) reported Increase (Decrease) in Accounts Receivable of -$433.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2020-05-07
- Trevi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-03-31 was -$433.00K.
- Trevi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-12-31 was $355.00K, a 446.15% increase year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-09-30 was -$48.00K, a 250.00% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-06-30 was $101.00K, a 405.00% increase year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2019 was $374.00K, a 177.04% increase from fiscal 2018.
- Trevi Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2018 was $135.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$433.00K 10-Q · filed 2020-05-07 | -$78.00K derived: sum of 2 quarters · filed 2020-05-07 | -$126.00K derived: sum of 3 quarters · filed 2020-05-07 | -$25.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $355.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $307.00K derived: sum of 2 quarters · filed 2020-03-16 | $408.00K derived: sum of 3 quarters · filed 2020-03-16 | $374.00K 10-K · filed 2020-03-16 |
| 2019-09-30 | -$48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $53.00K derived: sum of 2 quarters · filed 2019-11-14 | $19.00K 10-Q · filed 2019-11-14 | $84.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $67.00K 10-Q · filed 2019-08-12 | $132.00K derived: sum of 3 quarters · filed 2020-05-07 | $164.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | -$34.00K 10-Q · filed 2020-05-07 | $31.00K derived: sum of 2 quarters · filed 2020-05-07 | $63.00K derived: sum of 3 quarters · filed 2020-05-07 | $83.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $97.00K derived: sum of 2 quarters · filed 2020-03-16 | $117.00K derived: sum of 3 quarters · filed 2020-03-16 | $135.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $52.00K derived: sum of 2 quarters · filed 2019-11-14 | $70.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $38.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $18.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |